As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
Similar Posts
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).
MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines in latest blow to criminal network
Officers from the MHRA’s Criminal Enforcement Unit (CEU) have raided two separate premises as part of an ongoing investigation into an organised criminal network involved in the manufacture and sale of unlicensed weight loss medicines.
Decentralised Manufacture: UK Guideline of Good Pharmacovigilance Practices
Guidance covering various aspects of pharmacovigilance for authorised and unauthorised medicinal products (Specials and the Early Access to Medicines Scheme (EAMS)).
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
MHRA launches a consultation on indefinite recognition of CE-marked medical devices
Paracetamol and pregnancy – reminder that taking paracetamol during pregnancy remains safe
Patients should be reminded and reassured that there is no evidence that taking paracetamol during pregnancy causes autism in children. Paracetamol is recommended as the first-choice pain reliever for pregnant women, used at the lowest dose and for the shortest duration. It also acts as an antipyretic and is therefore used to treat fever.
MHRA Safety Roundup: January 2026
Summary of the latest safety advice for medicines and medical device users